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TheBacteroides are a numerically dominant genus of
the human intestinal microbiota. These organisms
harbor a rare bacterial pathway for incorporation of
exogenous fucose into capsular polysaccharides
and glycoproteins. The infrequency of glycoprotein
synthesis by bacteria prompted a more detailed
analysis of this process. Here, we demonstrate that
Bacteroides fragilis has a general O-glycosylation
system. The proteins targeted for glycosylation
include those predicted to be involved in protein
folding, protein-protein interactions, peptide degra-
dation as well as surface lipoproteins. Protein glyco-
sylation is central to thephysiology ofB. fragilis and is
necessary for the organism to competitively colonize
the mammalian intestine. We provide evidence that
general O-glycosylation systems are conserved
among intestinal Bacteroides species and likely
contribute to the predominance of Bacteroides in
the human intestine.
INTRODUCTION
The human intestine is home to one of the densest microbial
ecosystems in the world. In this intensely competitive environ-
ment, the best adapted microbial species colonize at high densi-
ties and persist for long periods (Ley et al., 2006; Whitman et al.,
1998). Members of the Bacteroides genus are specifically adap-
ted for survival in this ecosystem and collectively comprise one
of the most abundant bacterial genera in the human colon, in
some individuals accounting for 10%–20% of the microbial pop-
ulation (Eckburg et al., 2005; Kurokawa et al., 2007).
Intestinal microorganisms provide many functions essential to
the well-being of the host. The Bacteroides contribute to human
metabolism, development, and immunity. They provide energy
to the host in the form of short-chain fatty acids (Hooper et al.,
2002), and are involved in the recycling of bile acids (Midtvedt,
1974). During development, Bacteroides stimulate intestinalangiogenesis (Hooper et al., 2001) and induce local and systemic
immune functions (Hooper et al., 2003; Mazmanian et al., 2005).
The intestinal microbiota are also implicated in a number of major
health issues, including inflammatory bowel diseases, asthma
and other allergic disorders, colon cancer, and the spread of
antibiotic resistance (O’Keefe, 2008; Penders et al., 2007;
Salyers et al., 2004; Strober et al., 2007).
To better understand how these organisms affect the host both
beneficially and deleteriously, we need a more thorough analysis
of the bacterial mechanisms that are instrumental for their survival
in their ecosystem.Bacteroides spp.have several unique adapta-
tions that contribute to their successful habitation of this niche.
They can rapidly change their cell surface architecture through
the production of an unusually large number of phase-variable
capsular polysaccharides (Krinos et al., 2001), an adaptation
that appears specific to the intestinal environment, because it is
not found in closely related oral species (Coyne and Comstock,
2008). Bacteroides species also have an unprecedented reper-
toire of genetic systems devoted to acquiring and metabolizing
carbohydrates—including mucosal glycans and plant polysac-
charides that cannot be digestedby the host—whichallow a rapid
response to food supplies that are shifting and often times scarce
(Cerdeno-Tarraga et al., 2005; Xu et al., 2003, 2007). Also, at least
one Bacteroides species has been shown to stimulate the
expression of fucosylated glycoconjugates on the intestinal
epithelia of colonized mice (Bry et al., 1996).Bacteroides species
produce enzymes to harvest this fucose from host mucosal
glycans and have a rare bacterial pathway for incorporation of
this exogenous fucose directly into their capsular polysaccha-
rides and glycoproteins (Coyne et al., 2005). Recent studies
suggest that the ability of B. fragilis to synthesize fucosylated
glycoproteins is essential for it to competitively colonize the
mammalian intestine (Coyne et al., 2005, 2008).
Eukaryotic organisms have general N- and O-glycosylation
systems that modify as many as half of their cellular proteins,
but protein glycosylation is rare in bacteria. In those bacteria
that do glycosylate proteins, the glycosylated molecules are
usually limited to one or two abundant polymeric surface
proteins such as flagellins, pilins, and S-layer proteins (Benz
and Schmidt, 2002; Fletcher et al., 2007; Schaffer et al., 2001).
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are O-linked to serine and theronine residues. The only well-
characterized general glycosylation systems of bacteria are
those of Campylobacter jejuni and related species, where the
glycans are N-linked to asparagine residues (Szymanski et al.,
1999; Wacker et al., 2002), and a recently described O-glycosyl-
ation system of Neisseria gonorrhoeae (Vik et al., 2009).
Here, we investigated the production of fucosylated glycopro-
teins by B. fragilis. We demonstrate that this organism has
a general O-glycosylation system that is central to the physiology
of B. fragilis and its ability to colonize its ecological niche.
RESULTS
Identification of Eight Glycoproteins
We previously showed that B. fragilis produces many glycopro-
teins that bind the fucose-specific Aleuria aurantia lectin (AAL)
(Coyne et al., 2005), but no glycosylated proteins from this
species had been molecularly identified. For this, we used AAL
affinity chromatography to purify fucosylated molecules from
a whole-cell lysate and separated the AAL-purified fraction by
two-dimensional (2D) isoelectric focusing/PAGE (Figure 1A).
Ninety-five spots were excised from the 2D gel and individually
subjected to tandem mass spectrometry (MS/MS) analysis to
identify proteins. We unequivocally identified at least 1 protein
for 83 of the 95 spots, for a total of 48 different proteins (Figure 1A
and Table S1 available online).
Two of the most abundant proteins identified in this primary
screen were BF2494 and BF3567. We cloned the genes encod-
ing these proteins, expressed them in E. coli with His-tags, puri-
fied them, and used the purified proteins to immunize rabbits to
obtain antisera specific to the protein components of these
molecules. On western blots of B. fragilis whole-cell lysates,
each of these antisera recognized multiple bands with molecular
sizes slightly higher than predicted by the polypeptide
sequences, consistent with these molecules being glycosylated
(Figure 1B). The B. fragilis mutant Dgmd-fclDfkp is defective in
both pathways for biosynthesis of GDP-fucose and conse-
quently cannot incorporate fucose into glycoproteins (Coyne
et al., 2005). The BF2494 and BF3567 antisera each recognized
proteins of lower molecular weight in whole-cell lysates of this
mutant compared with wild-type, consistent with less or no
glycosylation of these proteins (Figure 1B).
Based on these observations, we developed a secondary
screen to assay for glycosylation of candidate proteins. We
modified the Bacteroides expression vector pFD340 (Smith
et al., 1992) so that a C-terminal His-tag was added to the
product of a cloned gene. This vector, pCMF6, allows us to
express proteins in B. fragilis and detect them with an antibody
to the His-tag or to purify them by nickel affinity chromatography.
We selected 24 candidate glycoproteins that were abundant on
the 2D gel and/or appeared in multiple spots, particularly diag-
onal ‘‘trains’’ that are typical of glycoforms. The genes of candi-
date proteins were cloned into pCMF6 and expressed in both
wild-type and Dgmd-fclDfkp. Whole-cell lysates were analyzed
by western blot using an antibody to the C-terminal His-tag. Of
the 24 candidates, 5 proteins in addition to BF2494 and
BF3567 were of smaller size in Dgmd-fclDfkp than in wild-type,
consistent with a glycosylation defect, 6 proteins showed no322 Cell 137, 321–331, April 17, 2009 ª2009 Elsevier Inc.change, and 11 were not produced in sufficient quantity to be de-
tected (Figure 1C and Table S1).
The seven proteins that had a reduced molecular size in
Dgmd-fclDfkp were subjected to additional analyses to confirm
glycosylation. Each of these seven His-tagged molecules was
purified from B. fragilis using nickel affinity chromatography
and its glycosylation was assayed by periodate-Schiff staining
and AAL reactivity. These tests were validated using His-tagged
BF2494 (BF2494-His) purified from both B. fragilis (glycosylated)
and E. coli (unglycosylated; Figure 1D). Glycosylation of six of
these proteins was confirmed by these methods (Figures 1D
and 1E). The seventh protein, BF0522, could not be purified in
sufficient quantity for these analyses, but positive results in
both the primary and secondary screens strongly suggest that
this molecule is glycosylated. An eighth protein, BF0994, was
not present in whole-cell lysates in sufficient quantity to be
detected in the secondary screen, but its glycosylation was
confirmed upon purification of the protein (Figure 1E). Thus, we
identified eight glycoproteins produced by B. fragilis (Table 1).
Next, we sought to determine if the glycan component of each
of these glycoproteins is similar. For this, we generated an anti-
serum specific to the glycan component of BF2494 by immu-
nizing rabbits with glycosylated BF2494-His purified from B. fra-
gilis, with subsequent removal of the antibodies to the protein
component using unglycosylated BF2494-His from E. coli immo-
bilized on a nickel column. The resulting adsorbed antiserum
recognizes glycosylated BF2494-His purified from B. fragilis
but not BF2494-His purified from E. coli (Figure 1D). Western
blot analysis demonstrated that this antiserum recognized
each of the other six purified glycoproteins, suggesting that their
glycans are similar or identical to those of BF2494 (Figure 1E).
The eight identified glycoproteins represent a variety of
biochemical activities (Table 1). BF0447 is similar to Skp of
E. coli, a chaperone of outer membrane proteins, and BF0994
has a sequence motif identifying it as a proline cis-trans isom-
erase, an activity usually associated with chaperone function
(Duguay and Silhavy, 2004). BF0935 and BF3918 have motifs
characteristic of zinc endopeptidases, whereas BF2334 and
BF2494 contain tetratricopeptide repeat (TPR) domains that
mediate protein-protein interactions. Therefore, B. fragilis glyco-
sylates proteins with a range of different functions, distinct from
the polymeric surface molecules that are typical of bacterial
glycoproteins.
Subcellular Localization of the Glycoproteins
The putative functions of the B. fragilis glycoproteins suggested
that many of them are likely internal rather than located on the
cell surface. All eight of the glycoproteins are predicted by LipoP
(Juncker et al., 2003) to have signal peptides. Three of the glyco-
proteins (BF0522, BF3567, and BF3918) are predicted to have
type II signal peptidase cleavage sites, indicating that they are
lipoproteins. The absence of an aspartate residue at position
+2 following the cleavage site indicates that these proteins are
targeted to the outer rather than the inner membrane (Yamagu-
chi et al., 1988).
The remaining five glycoproteins (BF0447, BF0935, BF0994,
BF2334, and BF2494) are predicted to have type I signal pepti-
dase cleavage sites and lack membrane targeting regions
Figure 1. Identification of Eight Glycoproteins
(A) 2D gel of AAL-purified proteins obtained from B. fragilis whole-cell lysate. Gene numbers indicate proteins that were unequivocally identified by MS analysis.
(B) Whole-cell lysates of wild-type (WT) and Dgmd-fclDfkp (DD), separated by SDS-PAGE, blotted and probed with antiserum to BF2494-His or BF3567-His puri-
fied from E. coli.
(C) Whole-cell lysates of wild-type (WT) and Dgmd-fclDfkp (DD) expressing His-tagged glycoprotein candidates, separated by SDS-PAGE, blotted and probed
with antibody to the His-tag. BF3810 is an example of a negative result.
(D) BF2494-His purified from B. fragilis (Bf) or E. coli (Ec), separated by SDS-PAGE and stained with Coomassie blue or Pro-Q Emerald Glycostain (first two
panels), or blotted and probed with AAL, antiserum to the glycan of BF2494, antibody to the His-tag, or anti-BF2494-His purified from E. coli.
(E) Six additional His-tagged glycoproteins purified from B. fragilis and analyzed as in (D).Cell 137, 321–331, April 17, 2009 ª2009 Elsevier Inc. 323
Table 1. Glycoproteins of B. fragilis
Gene Size (aa) Signala Subcellular Location Sequence Features
BF0447 169 I Periplasm Similar to E. coli
chaperone Skp
BF0522 210 II Outer membrane,
facing surface
—
BF0935 939 I Periplasm Zinc endopeptidase
(M16 family)
BF0994 712 I Periplasm Proline cis-trans
isomerase
(parvulin family)
BF2334 245 I Periplasm TPR domains
(residues 59–92
and 134–167)
BF2494 403b Ib Periplasm TPR domains
(residues 181–350)
BF3567 623 II Outer membrane,
facing surface
—




a Type of signal peptidase cleavage site predicted by LipoP (Juncker
et al., 2003).
b Translation of this protein appears to begin 7 codons upstream of the
start codon indicated by the genome annotation, making the protein
403 residues in length rather than 396. The longer sequence, unlike the
shorter one, is predicted to have a signal peptide by LipoP, consistent
with our experimental evidence showing that the protein is located in
the periplasm.suggesting that they are periplasmic. To confirm their localiza-
tions, we prepared cytoplasmic and periplasmic fractions from
wild-type B. fragilis for analysis of native BF2494, and from
wild-type expressing each of these five His-tagged glycopro-
teins. The purity of each fraction was determined by measuring
the activity of cytoplasmic and periplasmic marker enzymes
(Table S2). We analyzed the fractions by western blot with anti-
bodies to the protein component of BF2494 or to the His-tag.Figure 2. Subcellular Localization of the
Glycoproteins
(A) Cytoplasmic and periplasmic fractions of wild-
type B. fragilis, separated by SDS-PAGE, blotted
and probed with antiserum to BF2494-His purified
from E. coli.
(B) Cytoplasmic and periplasmic fractions from
B. fragilis expressing His-tagged BF2494, BF0447,
BF0935 or BF2334, separated by SDS-PAGE,
blotted and probed with anti-His-tag.
(C) Intact B. fragilis Dtsr15M8 cells were incubated
with proteinase K for the indicated times and the
lysate separated by SDS-PAGE, blotted and
probed with antisera to His-tagged BF3567,
AapA, or BF2494 purified from E. coli. BF2494
and AapA are controls located in the periplasm or
on the surface of the cell, respectively.
(D) Wild-type B. fragilis expressing BF0522-His or
BF3918-His were incubated with proteinase K for
the indicated times, lysed, separated by SDS-
PAGE, blotted and probed with anti-His-tag.324 Cell 137, 321–331, April 17, 2009 ª2009 Elsevier Inc.The results show that native BF2494 is targeted to the periplasm
(Figure 2A) as is BF2494-His (Figure 2B), validating the use of
these engineered proteins for localization experiments. BF0447-
His, BF0935-His, and BF2334-His are also located in the peri-
plasm (Figure 2B). BF0994-His was not detected by this method,
perhaps due to low abundance or solubility. However, given its
predicted function as a proline cis-trans isomerase, BF0994 is
likely to be located in the periplasm (Duguay and Silhavy, 2004).
The orientations of the three glycosylated outer membrane
lipoproteins (BF0522, BF3567, and BF3918) were next investi-
gated. Outer membrane lipoproteins of E. coli are generally
anchored in the inner leaflet of the membrane (Tokuda and Mat-
suyama, 2004), but in other Gram-negative bacteria, lipoproteins
are also present on the cell surface (Nsofor et al., 2006; Reilly
et al., 1999). To elucidate their localizations, whole bacteria
were treated with proteinase K to digest surface proteins. As
controls, we used BF2494, which we have shown here to be peri-
plasmic, and AapA, a cell surface protein (Weinacht et al., 2004).
BF3567 and BF0522-His were completely digested by
proteinase K treatment, demonstrating that they are cell surface
proteins (Figures 2C and 2D). BF3918-His was not digested, indi-
cating that it is likely anchored to the inner leaflet (Figure 2D).
Thus, all eight of these glycoproteins are secreted from the
cytoplasm and targeted either to the periplasm or the inner or
outer leaflet of the outer membrane (Table 1). Glycosylation of
periplasmic proteins is unusual: it has only been previously
observed for glycosylated proteins of C. jejuni, Desulfovibrio
gigas, and N. gonorrhoeae (Santos-Silva et al., 2007; Vik et al.,
2009; Young et al., 2002).
Glycosylation Sites in BF2494
BF2494 was selected as a prototype glycoprotein for more
detailed investigation due to its moderate size and abundance.
Glycans are most commonly attached to proteins by N-linkages
to asparagine or O-linkages to serine (S) and threonine (T). To
determine the nature of the protein-glycan linkage in BF2494,
BF2494-His was purified from B. fragilis and subjected to three
Figure 3. Site-Directed Mutagenesis of
BF2494
(A) Amino acid sequence of BF2494. The signal
peptide is underlined. Segments in upper case
and bolded are S/T-containing tryptic peptides
that were not detected in at least two of six MS
analyses of purified BF2494-His (excluding the
signal peptide). Boxed or underlined residues in
these segments were mutated to alanine to deter-
mine whether they are glycosylated; boxed resi-
dues were found to be glycosylated and under-
lined residues were not.
(B) Wild-type (WT) and mutant BF2494-His
proteins purified from B. fragilis, separated by
SDS-PAGE, blotted and probed with antiserum
to BF2494-His purified from E. coli or stained
with Coomassie blue.
(C) Same as (B) except that the gel was either
stained with Pro-Q Emerald Glycostain, or blotted
and probed with AAL or the antiserum to the
glycan of BF2494.
(D) Cytoplasmic and periplasmic fractions of
B. fragilis expressing His-tagged BF2494 D(2-18),
separated by SDS-PAGE, blotted and probed with
anti-His-tag. The periplasmic fraction is signifi-
cantly contaminated with cytoplasmic material
but the His-tagged protein is partitioned between
the fractions in the proportions expected for
a cytoplasmic molecule (Table S2).
(E) Same as (D) except that the protein is the triple
T/A BF2494-His molecule.
(F) Alignment of protein sequences surrounding the three glycosylation sites of BF2494. Glycosylated residues are underlined and conserved or similar residues
are bold.
(G) Whole-cell lysates of B. fragilis expressing wild-type and various mutant BF2494-His proteins, separated by SDS-PAGE, blotted and probed with antibody to
the His-tag.procedures to release glycans from the proteins: b-elimination,
which releases glycans that are O-linked to S or T, and two
different hydrazinolysis procedures optimized to release either
O-linked glycans, or both N- and O-linked glycans. All three
procedures released oligosaccharides, suggesting that this
protein has glycans O-linked to S and T (data not shown).
Given this information, site-directed mutagenesis was used
to identify the glycosylation sites of BF2494 and confirm the
O-linkages to S and T. BF2494 contains 22 S and T residues.
To identify residues likely to be glycosylated, we focused on
tryptic peptides that were not frequently detected by MS/MS
analysis of BF2494 due to a mass increase from glycosylation.
Nine S and T residues were present in rarely observed peptides
(Figure 3A). Each of these nine residues was individually mutated
to alanine and the resulting proteins were purified from B. fragilis
and analyzed by western blot to detect changes in molecular
weight resulting from lack of glycosylation at the mutated site.
Mutation of candidate residues T60, S123, S126, T188, T309,
and S321 had no detectable effect (data not shown). However,
mutation of T87, T178, or T231 to alanine resulted in loss of the
largest form of the molecule (Figure 3B). Mutation of two of these
three residues in any combination resulted in loss of the two
largest forms, whereas mutation of all three residues resulted
in a single form of lower molecular weight than any form
observed for the wild-type glycoprotein (Figure 3B). Further-
more, all three double T/A mutants are still glycosylated, butthe triple mutant is not (Figure 3C). Cell fractionation showed
that the triple T/A mutant protein is present in the periplasm,
so its lack of glycosylation is not due to incorrect localization
(Figure 3E). These results demonstrate that T87, T178, and
T231 are the only glycosylation sites of BF2494, and therefore
all the glycans of this protein are O-linked.
Inspection of the protein sequence around the three glycosyl-
ation sites of BF2494 revealed that each has an aspartate (D)
preceding the glycosylated T and is followed by an amino acid
with one or more methyl groups (alanine, isoleucine, or leucine;
Figure 3F). None of the 17 unglycosylated S and T residues of
BF2494 (excluding two in the signal peptide) have a preceding
D, although seven are followed by A, I, or L and one by V. Further-
more, the other seven identified glycoproteins all contain at least
one site with this motif. Because O-glycosylation systems in
other organisms do not require a motif other than S or T, we
made site-directed mutations of the putative glycosylation site
around T231 of BF2494. The predicted three-residue glycosyla-
tion site motif (D)(S/T)(A/I/L/V) was first tested by altering the first
residue, D230, to either an A, or the most conservative substitu-
tion, glutamate (E). These alterations were not tolerated and re-
sulted in lack of glycosylation at this site (Figure 3G). The second
residue of the motif, T231, was changed to an S, which did not
alter glycosylation and therefore could be used interchangeably
as the glycosylated residue. The third residue of the motif was
predicted to require a methyl group. Substitution of the A232Cell 137, 321–331, April 17, 2009 ª2009 Elsevier Inc. 325
Figure 4. A Genomic Region Involved in Protein Glycosylation
(A) The region of the B. fragilis genome containing metG and genes BF4298-4306. Putative glycosyltransferase genes are hatched.
(B) Phosphoimager scan of SDS-PAGE-separated whole-cell lysates of wild-type,Dgmd-fclDfkp, and D(BF4298-4306) grown in a medium containing 3H-fucose.
(C) Whole-cell lysates of wild-type and mutants separated by SDS-PAGE, blotted and probed with antiserum to BF2494-His purified from E. coli.
(D) Whole-cell lysates of wild-type and mutant B. fragilis expressing BF0447-His or BF0522-His, separated by SDS-PAGE, blotted and probed with anti-His-tag.
(E) RT-PCR amplification of a 1142 bp region including portions of the coding regions of metG and wzx, as indicated in (A). Reactions were performed with and
without reverse transcriptase (RT).at the third position with either of the two remaining methyl con-
taining residues, methionine (M) or T, were tolerated; however,
substitution with the non-methyl-containing residues D or
glycine (G) abrogated glycosylation at this site (Figure 3G).
Therefore, the glycoyslation motif of the O-glycosylation system
of B. fragilis is (D)(S/T)(A/I/L/V/M/T). A similar O-glycosylation
motif has been predicted in Elizabethkingia meningoseptica,
which belongs to the same phylum as B. fragilis (Plummer
et al., 1995).
Glycosylation of BF2494 Requires Secretion
into the Periplasm
Most glycosylation systems modify proteins that have been
transported out of the cytoplasm, into the bacterial periplasm
or the endoplasmic reticulum (ER) and Golgi of eukaryotic cells
(Szymanski and Wren, 2005). To test if secretion into the peri-
plasm is required for protein glycosylation in B. fragilis, we
mutated BF2494-His so that all but the first and last residues
of the signal peptide were removed (amino acids 2–18;
Figure 3A) and expressed this mutant protein in B. fragilis. Frac-
tionation confirmed that this signal peptide mutant is retained in
the cytoplasm (Figure 3D). Moreover, the purified mutant protein
is not glycosylated (Figure 3C) and has the same molecular
size as the triple glycosylation site mutant described above
(Figure 3B).
A Genomic Region Involved in Protein Glycosylation
B. fragilis strain 9343 produces eight different capsular polysac-
charides, each synthesized by the products of separate operons
(Krinos et al., 2001). As in many bacteria, the repeat units of the
capsular polysaccharides are assembled at the inner surface of
the cytoplasmic membrane, transported across the membrane326 Cell 137, 321–331, April 17, 2009 ª2009 Elsevier Inc.by a polysaccharide flippase (Wzx) and polymerized by a poly-
saccharide polymerase (Wzy). Each of the eight capsular poly-
saccharide operons encodes both a flippase and a polymerase.
As secretion into the periplasm is necessary for protein glycosyl-
ation, a genomic region involved in protein glycosylation would
likely encode a flippase, but would lack a polymerase. On in-
specting the B. fragilis genome, we found a region spanning
genes BF4298 to BF4306 that encodes a putative flippase, five
putative glycosyltransferases, and other genes likely to be
involved in oligosaccharide synthesis, but no polymerase
(Figure 4A and Table S3).
We deleted all nine of these genes and examined the effect of
this deletion on protein glycosylation. We previously showed that
wild-type B. fragilis incorporates 3H-fucose from its growth
medium into glycoproteins and that Dgmd-fclDfkp is deficient
in this process (Coyne et al., 2005). Figure 4B shows that mutant
D(BF4298-4306) also can not incorporate 3H-fucose into glyco-
proteins. As a further test, we compared the sizes of three His-
tagged glycoproteins expressed in wild-type B. fragilis and
D(BF4298-4306). All three glycoproteins were of lower molecular
weight in the mutant, identical to their sizes in Dgmd-fclDfkp,
consistent with a glycosylation defect (Figures 4C and 4D).
These results demonstrate that the BF4298-4306 region is
involved in protein glycosylation. Furthermore, because this
region is required for synthesis of all the fucosylated glycopro-
teins, it appears to be part of a general glycosylation system.
Based on these results, we named the BF4298-4306 region lfg
for locus of fragilis glycosylation.
Interestingly, the lfg region is adjacent to metG, which
encodes the essential enzyme methionyl-tRNA synthetase
(Figure 4A). metG and wzx (BF4298) are transcribed in the
same direction and are separated by only 90 bp, with no
Figure 5. Conservation of Protein Glycosylation in the Intestinal Bacteroides
(A) The lfg region of B. fragilis and the corresponding regions downstream of metG in other intestinal Bacteroides species. Putative glycosyltransferases are
hatched.
(B) Whole-cell lysates of various Bacteroides species separated by SDS-PAGE, blotted and probed with antiserum to the glycan of BF2494.
(C) Same as (B) except that the blot was probed with antiserum to BF2494 purified from E. coli, which recognizes the protein component of the molecule.
(D) Alignment of segments of BF2494 and its orthologs demonstrating conservation of the glycosylation motif (bolded). The three residues that are glycosylated in
B. fragilis (T87, T178 and T231), and its counterparts in the orthologous proteins are underlined.
(E) Western blot analysis of whole-cell lysates of various Bacteroides species expressing the B. fragilis wild-type BF2494-His protein (WT), or the B. fragilis
BF2494-His triple glycosylation site mutant (T87A.T178A.T231A), probed with anti-His-tag.recognizable B. fragilis promoter (Bayley et al., 2000) in the inter-
vening region. We used reverse transcriptase polymerase chain
reaction (RT-PCR) to amplify a region including part of the coding
regions of both metG and wzx and confirmed that these genes
are cotranscribed (Figure 4E). The transcriptional linkage of the
protein translation machinery (metG) with the protein glycosyla-
tion machinery (lfg) suggests a high level of importance for
protein glycosylation in B. fragilis.
Two other important features of the lfg region distinguish it
from the capsular polysaccharide biosynthesis loci. The capsular
polysaccharide loci have a low G+C content (32.6%–37.9%)
compared with the G+C content of the genome (42.3%), indi-
cating relatively recent acquisitions by horizontal transfer events.
In contrast, the G+C content of the lfg region is 45.4%, similar
to that of the genome and the adjacent housekeeping gene
metG (47.0%). In addition, analysis of the two other sequenced
B. fragilis genomes reveals that the lfg region is highly conserved
(the nine encoded proteins are 98.8%–100% identical between
strains), whereas the capsular polysaccharide loci are heteroge-
neous (Comstock et al., 2000; Coyne et al., 2001). Therefore, the
lfg region is likely evolutionarily ancient and essential for survival
of the organism in its niche.Conservation of Protein Glycosylation in the Intestinal
Bacteroides
Our analysis of five other intestinal Bacteroides species (B. cac-
cae, B. ovatus, B. thetaiotaomicron, B. uniformis, B. vulgatus)
demonstrated that they all have regions similar to lfg, with a flip-
pase gene downstream of metG and several glycosyltransferase
genes (Figure 5A). This finding, coupled with our previous obser-
vation that other Bacteroides species produce fucosylated
glycoproteins (Coyne et al., 2005), prompted us to investigate
if the general O-glycosylation system of B. fragilis is conserved
in other intestinal Bacteroides species.
We used the glycan-specific antiserum described above in
western blots of whole-cell lysates of all five species. Figure 5B
shows that this antiserum recognizes many molecules in all the
Bacteroides species analyzed, indicating that these species
modify their proteins with a glycan similar to that of B. fragilis
(Figure 5B). Furthermore, this antiserum recognizes a similar
pattern of molecules in these species, suggesting that ortholo-
gous proteins of each species are glycosylated (Figure 5B).
There are conserved orthologs of the B. fragilis glycoprotein
BF2494 in four of the five other intestinal Bacteroides species
analyzed (70%–75% identity, 82%–88% similarity), with theCell 137, 321–331, April 17, 2009 ª2009 Elsevier Inc. 327
B. vulgatus BF2494 ortholog demonstrating only 39% identity
and 56% similarity. When we probed whole-cell lysates of these
five other Bacteroides species with antiserum to the protein
component of BF2494, orthologs of the expected molecular
weight were detected in all species except B. vulgatus. In each
species, the antiserum recognized molecules of multiple sizes,
suggesting that the BF2494 orthologs have various glycoforms
(Figure 5C).
Alignment of the sequence of BF2494 with its orthologs shows
that the three glycosylation sites of the B. fragilis molecule align
with sequences from the other five orthologs that match
perfectly with the glycosylation motif (D)(S/T)(A/I/L/V/M/T)
(Figure 5D). This finding suggests that the same three sites are
glycosylated in these BF2494 orthologs. Therefore, B. fragilis
BF2494 should be glycosylated at these same three sites if
transferred into these species. To test this prediction, we ex-
pressed B. fragilis BF2494-His and the BF2494-His triple glyco-
sylation site mutant T87A.T178A.T231A in four otherBacteroides
species. When whole-cell lysates from these bacteria were
probed with antibody to the His-tag, the B. fragilis 2494-His
protein displayed multiple bands in each of these species, indic-
ative of multiple glycoforms, whereas the 2494-His triple glyco-
sylation site mutant was of a single, lower molecular size and
was much less abundant, consistent with our observations in
B. fragilis (Figure 5E). Together with the preceding results, these
data suggest that these intestinal Bacteroides species have
similar general O-glycosylation systems.
Protein Glycosylation Affects B. fragilis Growth
Because our results suggested that protein glycosylation is an
important process in B. fragilis, we carried out experiments to
determine whether the attenuation of protein glycosylation in
Dlfg and Dgmd-fclDfkp affects growth of the bacterium. We
found significant in vitro growth defects in both of these mutants.
Most dramatically, both mutants had fewer viable cells at all
stages of growth compared with the wild-type (Figure S1). This
result is consistent with a central role for protein glycosylation
in B. fragilis physiology.
Protein Glycosylation Is Required for Competitive
Colonization of Gnotobiotic Mice
We tested the importance of protein glycosylation for intestinal
colonization using Dlfg in a gnotobiotic mouse model. When
mice were monoassociated with Dlfg, it achieved a density of
2–43 1010 cfu per gram of fecal material from the first measure-
ment (3 days after inoculation) to the end of the experiment
(12 days). This is the same level we have previously observed
for wild-type B. fragilis (Coyne et al., 2005) and indicates that
the mutant is equally able to colonize the mouse intestine in
the absence of competition. However, Dlfg is not able to
compete with wild-type B. fragilis for intestinal colonization. In
three separate experiments, even with a 4:1 numerical advan-
tage in the initial inocula, the mutant strain was reduced to a small
minority of the bacteria in fecal samples 3 days after inoculation,
and was almost undetectable after 7 days (Table 2). These
results show that protein glycosylation is required for B. fragilis
to colonize its ecological niche.328 Cell 137, 321–331, April 17, 2009 ª2009 Elsevier Inc.Table 2. Competitive Colonization of Gnotobiotic Mice
Cage Numbera
% Dlfgb
Innoculum Day 3 Day 7
1 80 6 0
2 80 7 0
3 78 16 1
a Each cage contained two mice; fecal samples from both mice in each
cage were pooled for analysis.
b Percentage of bacterial colonies from the innoculum culture or mouse
fecal samples that were Dlfg rather than wild-type.DISCUSSION
In this paper, we investigated the production of fucosylated
glycoproteins by B. fragilis. We identified eight glycoproteins
with similar or identical glycans, which are located in the peri-
plasm or outer membrane and have a variety of predicted func-
tions. Based on the number of glycoprotein candidates identified
in our primary screen (48) and the success rate of the secondary
screen and confirmation procedure (8 of 14 proteins detected
were proven to be glycosylated), we expect that at least 20 of
these 48 proteins are glycosylated. We showed that a prototype
glycoprotein is O-glycosylated and confirmed that glycosylation
requires a three-residue motif. Furthermore, deletion of a single
genomic region affected all of the fucosylated glycoproteins.
Taken together, these results indicate that B. fragilis has
a general O-glycosylation system, one of the few described
general glycosylation systems in bacteria. The well-character-
ized general N-glycosylation system of C. jejuni appears to be
conserved in closely related species (Szymanski and Wren,
2005), much as the general O-glycosylation system of B. fragilis
is conserved in other intestinal Bacteroides species.
The predicted functions of the glycoproteins BF0447 and
BF0994 suggest that they are involved in a chaperone system,
possibly serving as chaperones of outer membrane proteins
like that described for E. coli (Duguay and Silhavy, 2004). Other
glycoproteins may be involved in the response to oxidative
stress suggested by a recent study in which BF0522 and
BF2334 were upregulated 6.1- and 3.9-fold, respectively, on
exposure of B. fragilis to air (Sund et al., 2008). BF4280, which
was detected in our primary screen, has been implicated in
binding to the host protein plasminogen (Sijbrandi et al., 2008).
Therefore, glycoproteins might also contribute to the pathogen-
esis of B. fragilis in extraintestinal infections.
The contributions of glycans to protein function can be placed
in two broad categories: providing labels for binding and recog-
nition by other proteins (Haltiwanger and Lowe, 2004; Helenius
and Aebi, 2004), and stabilizing proteins, including thermody-
namic stability, solubility, and protection from proteases (Langs-
ford et al., 1987; Meldgaard and Svendsen, 1994; Nakatsukasa
et al., 2004). Protein glycosylation in B. fragilis might provide
a stabilizing function, because we do not observe unglycosy-
lated forms in wild-type bacteria (Figures 1D, 1E, and 2B), and
the triple T/A unglycosylated mutant of BF2494 is expressed
at an extremely reduced level (Figure 5D). It was recently re-
ported that periplasmic proteins of B. fragilis do not form
intramolecular disulfide bonds (Dutton et al., 2008). Therefore,
protein glycosylation might provide an alternative means of
protein stabilization.
The mechanism of O-glycosylation in B. fragilis appears to
have some similarities to protein glycosylation in other bacteria,
which itself is similar to eukaryotic N-glycosylation (Szymanski
and Wren, 2005). The likely common features are assembly of
the glycan on a lipid carrier by cytoplasmic glycosyltransferases
using nucleotide-activated sugar substrates, flipping of the
glycan into the periplasm (the ER in eukaryotes), with subse-
quent block transfer of the oligosaccharide to the protein.
B. fragilis O-glycosylation therefore appears to be similar to pilin
O-glycosylation in bacteria (Faridmoayer et al., 2007) and to
a recently described S-layer O-glycosylation system of Geoba-
cillus stearothermophilus (Steiner et al., 2008), but different
than O-glycosylation in eukaryotes, which generally involves
sequential transfer of monosaccharides to proteins. A proposed
model for the general O-glycosylation pathway of B. fragilis is
shown in Figure S2.
Several lines of evidence suggest that protein glycosylation is
central to B. fragilis physiology; the substantial number of
proteins that are glycosylated, their various locations both inside
and outside the cell, their variety of biochemical functions, and
their possible roles in fundamental processes such as protein
folding. Second, we do not observe unglycosylated forms of
the glycoproteins, suggesting that glycosylation is essential for
their function. In addition, the transcriptional linkage of the lfg
region to metG, a gene required for translation of essentially all
proteins made by the organism, suggests that the protein glyco-
sylation system is a vital component of the protein synthesis
machinery. Lastly, deletion of the lfg region results in a substan-
tial growth deficiency in vitro and a complete inability to compete
with wild-type bacteria in the mouse intestine. The conservation
of the glycosylation system in all of the intestinal Bacteroides
species examined suggests that it contributes to the predomi-
nance of these organisms in the human intestine.
EXPERIMENTAL PROCEDURES
All oligonucleotides used in this study are listed in Table S4.
2D Gels
A total of 500 mg protein eluted from an AAL affinity column was resuspended
in 7 M urea, 2 M thiourea, 50 mM DTT, 0.5% Pharmalyte 3-11, 0.4% CHAPS
and focused on 24 cm pH 3-11 nonlinear IPG strips (GE Healthcare). These
were reduced, alkylated, and loaded onto 25 3 25 cm 12%–25%T polyacryl-
amide gels, which were run at 10C, fixed, and stained with Coomassie blue.
Spots were visualized with an Odyssey 700 nm laser (Li-Cor) and images
analyzed using Delta2D (Decodon, Germany). Background was defined as
any non-Gaussian pixel array and subtracted from the image. Spots were
excised for identification by MS as described in Supplemental Experimental
Procedures.
Expression and Purification of His-Tagged Proteins from E. coli
The coding regions of BF2494 and BF3567 were amplified from chromosomal
DNA and ligated into the NcoI site of pET16b to produce proteins with
C-terminal His-tags. The resulting plasmids were transformed into E. coli
BL21(DE3). His-tagged proteins were purified using ProBond resin (Invitrogen)
under denaturing conditions.Expression of His-Tagged Proteins in B. fragilis
pFD340 (Smith et al., 1992) was modified to produce proteins from cloned
genes with C-terminal His-tags. A double-stranded insert encoding 10 histi-
dine residues with a stop codon and SstI/BamHI ends was created by anneal-
ing two oligonucleotides and cloned into SstI/BamHI-digested pFD340
creating pCMF6. The coding regions and ribosome binding sites of candidate
glycoproteins were amplified from the B. fragilis chromosome, digested with
BamHI or BglII, and ligated into the BamHI site of pCMF6. The recombinant
proteins are modified by addition of the amino acids GSH10 at the C terminus.
Purification of His-Tagged Proteins from B. fragilis
Cultures (2 L) of B. fragilis harboring plasmids encoding His-tagged proteins
were grown to stationary phase and harvested. His-tagged proteins were puri-
fied using 0.5 ml Ni-NTA agarose resin (Invitrogen). Cells were resuspended in
buffers containing an EDTA-free Complete Protease Inhibitor Tablet (Roche)
and lysed by sonication. Membrane-associated proteins were purified under
denaturing conditions, washed with 16 ml buffer at each of pH 8.0, 6.0, and
5.3 and eluted at pH 4.0. Soluble proteins were purified under native conditions
with 16 ml washes containing 0 and 20 mM imidazole, a final wash with 16 ml
buffer containing 1 mM EDTA, and eluted with 250 mM imidazole.
Antibodies
To generate antisera specific to BF2494 and BF3567, His-tagged molecules
were purified from E. coli and used to immunize rabbits using the EXPRESS-
LINE protocol of Lampire Biological Laboratories. Antiserum was generated
in the same way to glycosylated BF2494-His purified from B. fragilis. Anti-
bodies to the protein component of BF2494 were adsorbed from this anti-
serum by incubation with BF2494-His purified from E. coli immobilized on Pro-
Bond resin. This adsorption was performed twice and the flow-through
antiserum was confirmed to be devoid of antibodies to 2494-His of E. coli. A
monoclonal antibody to C-terminal His-tag was purchased from Invitrogen.
Fractionation of Cytoplasm and Periplasm
Fractionation was achieved as previously described (Salyers and Kotarski,
1980) with a 4 min incubation for spheroplast formation. The amount of cyto-
plasmic and periplasmic material in each fraction was determined by assaying
the activity of the cytoplasmic enzyme phosphoglucose isomerase (Noltz-
mann, 1966) and the periplasmic enzyme alkaline phosphatase (Garen and
Levinthal, 1960).
Whole-Cell Proteolysis
Proteolysis was carried out as previously described (Shipman et al., 1999)
except the buffer was phosphate-buffered saline (PBS) containing 10 mM
MgCl2. To determine the orientation of BF3567, we used B. fragilis Dtsr15M8,
in which the invertible promoter of the aap operon is locked in the ON position,
giving increased expression of AapA (Weinacht et al., 2004). Because our
proteinase K treatment was sufficient to degrade AapA (external control) but
did not affect BF2494 (internal control), we used the same treatment to deter-
mine the orientations of BF0522-His and BF3918-His expressed in wild-type
B. fragilis.
Site-Directed Mutagenesis
Site-directed mutagenesis of the BF2494 coding sequence in plasmid pCMF6
was carried out with the QuikChange XL Kit (Stratagene) with an elongation
time of 12 min. All mutations were confirmed by sequencing.
Deletion of the lfg Region
A total of 10,040 bp of DNA were deleted, including all but the first 23 bp of the
coding region of BF4298 and the last 33 bp of BF4306. DNA segments flanking
the region to be deleted were amplified from the chromosome, digested with
BamHI and MluI and ligated together into the BamHI site of the suicide vector
pJST55 (Thompson and Malamy, 1990). After conjugal transfer to B. fragilis,
cointegrates resulting from homologous recombination were selected for
erythromycin (Em) resistance, passaged, plated on nonselective medium,
and replica plated onto medium containing Em. EmS colonies were screened
by PCR to identify mutants.Cell 137, 321–331, April 17, 2009 ª2009 Elsevier Inc. 329
RT-PCR
B. fragilis was grown to OD600 0.8, harvested, and total RNA was extracted
with the RNeasy Mini Kit using RNAprotect with on-column digestion using
the RNase-Free DNase Set (all products from QIAGEN) and further DNase
treatment was performed with the DNA-free kit (Ambion). RT-PCR was per-
formed using 100 ng RNA with the SuperScript III One-Step RT-PCR System
with Platinum Taq DNA Polymerase (Invitrogen). A separate set of reactions
was performed that included Taq but no RT. The primers encompassed
a region of 1142 bp including the last 928 bp of the coding region of metG
and the first 121 bp of BF4298.
Colonization of Gnotibiotic Mice
Mouse studies were approved by the Harvard Medical Area standing
committee on animals. Male Swiss Webster germ-free mice (3–5 weeks old)
were purchased from Taconic. The mice were housed in gnotobiotic isolators
and fed an autoclaved rodent chow diet (Zeigler Bros). Mice were innoculated
with bacteria by spreading log-phase cultures on their fur. For monoassocia-
tion assays, we used one cage containing two mice. Fresh fecal samples
were collected at various intervals, diluted in PBS, and plated for colony
counts. For competitive colonization assays, we used three cages of two
mice each. Wild-type and Dlfg strains from fecal samples and the innoculum
culture were identified by performing colony PCR with a mixture of primers, re-
sulting in a 770 bp product from wild-type and a 460 bp product from the
mutant. We screened 96 colonies from each cage at each time point.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, four
tables, and two figures and and can be found with this article online at
http://www.cell.com/supplemental/S0092-8674(09)00255-4.
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